Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for gaucher disease

Journal of Medicinal Chemistry

Volumn 53, Issue 14, 2010, Pages 5248-5255

  Díaz, Lucía ^a   Bujons, Jordi ^b   Casas, Josefina ^b   Llebaria, Amadeu ^b   Delgado, Antonio ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; AMINOCYCLITOL; CHAPERONE;

ARTICLE; DRUG ACTIVITY; DRUG INDICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GAUCHER DISEASE; LIPOPHILICITY; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION;

CYCLITOLS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 77954749600     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100198t     Document Type: Article

References (50)

1. Brady, R. O. Gaucher's disease: past, present and future Baillieres Clin. Haematol. 1997, 10, 621-634
2. Sawkar, A. R.; D'Haeze, W.; Kelly, J. W. Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease Cell. Mol. Life Sci. 2006, 63, 1179-1192
3. Morello, J.-P.; Bouvier, M.; Petaja-Repo, U. E.; Bichet, D. G. Pharmacological chaperones: a new twist on receptor folding Trends Pharmacol. Sci. 2000, 21, 466-469
4. Fan, J.-Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity Trends Pharmacol. Sci. 2003, 24, 355-360
5. Butters, T. D. Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders Expert Opin. Pharmacother. 2007, 8, 427-435
6. Grabowski, G. A. Treatment perspectives for the lysosomal storage diseases Expert Opin. Emerging Drugs 2008, 13, 197-211
7. Dvir, H.; Harel, M.; McCarthy, A. A.; Toker, L.; Silman, I.; Futerman, A. H.; Sussman, J. L. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease EMBO Rep. 2003, 4, 704-709
8. Brumshtein, B.; Wormald, M. R.; Silman, I.; Futerman, A. H.; Sussman, J. L. Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 1458-1465
9. Shaaltiel, Y.; Bartfeld, D.; Hashmueli, S.; Baum, G.; Brill-Almon, E.; Galili, G.; Dym, O.; Boldin-Adamsky, S. A.; Silman, I.; Sussman, J. L.; Futerman, A. H.; Aviezer, D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system Plant Biotechnol. J. 2007, 5, 579-590
10. Brumshtein, B.; Salinas, P.; Peterson, B.; Chan, V.; Silman, I.; Sussman, J. L.; Savickas, P. J.; Robinson, G. S.; Futerman, A. H. Characterization of gene-activated human acid-{beta}-glucosidase: crystal structure, glycan composition and internalization into macrophages Glycobiology 2010, 20, 24-32
11. Lieberman, R. L.; D'Aquino, J, A.; Ringe, D.; Petsko, G. A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 2009, 48, 4816-4827
12. Kacher, Y.; Brumshtein, B.; Boldin-Adamsky, S.; Toker, L.; Shainskaya, A.; Silman, I.; Sussman, J. L.; Futerman, A. H. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy Biol. Chem. 2008, 389, 1361-1369
13. Premkumar, L.; Sawkar, A. R.; Boldin-Adamsky, S.; Toker, L.; Silman, I.; Kelly, J. W.; Futerman, A. H.; Sussman, J. L. X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease J. Biol. Chem. 2005, 280, 23815-23819
14. Brumshtein, B.; Greenblatt, H. M.; Butters, T. D.; Shaaltiel, Y.; Aviezer, D.; Silman, I.; Futerman, A. H.; Sussman, J. L. Crystal structures of complexes of N -butyl- and N -nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease J. Biol. Chem. 2007, 282, 29052-29058
15. Lieberman, R. L.; Wustman, B. A.; Huertas, P.; Powe, A. C., Jr.; Pine, C. W.; Khanna, R.; Schlossmacher, M. G.; Ringe, D.; Petsko, G. A. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease Nat. Chem. Biol. 2007, 3, 101-107
16. Brumshtein, B.; Aguilar-Moncayo, M.; Garcia-Moreno, M. I.; Ortiz Mellet, C.; Garcia Fernandez, J. M.; Silman, I.; Shaaltiel, Y.; Aviezer, D.; Sussman, J. L.; Futerman, A. H. 6-Amino-6-deoxy-5,6-di- N -(N ′- octyliminomethylidene)nojirimycin: synthesis, biological evaluation, and crystal structure in complex with acid beta-glucosidase ChemBioChem 2009, 10, 1480-1485
17. Egido-Gabas, M.; Serrano, P.; Casas, J.; Llebaria, A.; Delgado, A. New aminocyclitols as modulators of glucosylceramide metabolism Org. Biomol. Chem. 2005, 3, 1195-1201
18. Egido-Gabas, M.; Serrano, P.; Casas, J.; Zucco, M.; Emeric, G.; Llebaria, A.; Delgado, A. New aminocyclitol libraries as candidates to chemical chaperone therapy for Gaucher disease Naunyn-Schmiedeberg's Arch. Pharmacol. 2007, 374, 340
19. Egido-Gabas, M.; Canals, D.; Casas, J.; Llebaria, A.; Delgado, A. Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease ChemMedChem 2007, 2, 992-994
20. Sanchez-Olle, G.; Duque, J.; Egido-Gabas, M.; Casas, J.; Lluch, M.; Chabas, A.; Grinberg, D.; Vilageliu, L. Promising results of the chaperone effect caused by iminosugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease Blood Cells, Mol. Dis. 2009, 42, 159-166
21. Serrano, P.; Casas, J.; Zucco, M.; Emeric, G.; Egido-Gabas, M.; Llebaria, A.; Delgado, A. Combinatorial approach to N-substituted aminocyclitol libraries by solution-phase parallel synthesis and preliminary evaluation as glucocerebrosidase inhibitors J. Comb. Chem 2007, 9, 43-52
22. Serrano, P.; Llebaria, A.; Delgado, A. Regio- and stereoselective synthesis of aminoinositols and 1,2-diaminoinositols from conduritol B epoxide J. Org. Chem. 2005, 70, 7829-7840
23. Serrano, P.; Llebaria, A.; Vazquez, J.; de Pablo, J.; Anglada, J. M.; Delgado, A. On the regio- and stereoselective synthesis of aminocyclitols from cyclitol epoxides: the effect of Li as a chelating agent Chem. - Eur. J. 2005, 11, 4465-4472
24. The recovery of recombinant GlcCerase activity after thermal denaturation is currently used as an in vitro model assay for potential pharmacological chaperones (see ref 37).
25. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 41, 2596-2599
26. Gil, M. V.; Arévalo, M. J.; López, O. Click chemistry - What's in a name? Triazole synthesis and beyond Synthesis 2007, 1589-1620
27. Gonzalez-Bulnes, P.; Casas, J.; Delgado, A.; Llebaria, A. Practical synthesis of (-)-1-amino-1-deoxy-myo-inositol from achiral precursors Carbohydr. Res. 2007, 342, 1947-1952
28. 50 values below 40 μM at pH 5.0 (pH for optimal enzyme activity).
29. Only compounds 2b, 2c, and 3a showed GCS inhibition (A549 cells), albeit not higher than 30% at the indicated concentration (250 μM). For a matter of comparison, a 70% inhibition of enzyme activity was found for NBDNJ at 10 μM. For experimental details, see the Supporting Information.
30. Compounds were screened against the following glycosidases: sweet almond β-glucosidase, yeast α-glucosidase, rice α-glucosidase, rice α-galactosidase, and bovine liver β-galactosidase. For further details, see the Supporting Information.
31. i ratio as a measure of compound efficacy, the following values are obtained: 1c ≥ 900; 1d ≥ 3300; 1e = 916; 1f = 237.
32. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931
33. Guimaraes, C. R.; Cardozo, M. MM-GB/SA rescoring of docking poses in structure-based lead optimization J. Chem. Inf. Model. 2008, 48, 958-970
34. Brik, A.; Alexandratos, J.; Lin, Y. C.; Elder, J. H.; Olson, A. J.; Wlodawer, A.; Goodsell, D. S.; Wong, C. H. 1,2,3-Triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors ChemBioChem 2005, 6, 1167-1169
35. Appendino, G.; Bacchiega, S.; Minassi, A.; Cascio, M. G.; De Petrocellis, L.; Di Marzo, V. The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and cannabinoids Angew. Chem., Int. Ed. 2007, 46, 9312-9315
36. Odlo, K.; Hentzen, J.; dit Chabert, J. F.; Ducki, S.; Gani, O. A.; Sylte, I.; Skrede, M.; Florenes, V. A.; Hansen, T. V. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin Bioorg. Med. Chem. 2008, 16, 4829-4838
37. Sawkar, A. R.; Cheng, W. C.; Beutler, E.; Wong, C. H.; Balch, W. E.; Kelly, J. W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15428-15433
38. Maestro, version 8.5; Schrödinger, LLC: New York, 2008.
39. MacroModel, version 9.6; Schrödinger, LLC: New York, 2005.
40. Jorgensen, W. L.; Maxwell, D. S.; TiradoRives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
41. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics J. Am. Chem. Soc. 1990, 112, 6127-6129
42. Glide, version 5.0; Schrödinger, LLC: New York, 2008.
43. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
44. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759
45. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
46. Klicic, J. J.; Friesner, R. A.; Liu, S. Y.; Guida, W. C. Accurate prediction of acidity constants in aqueous solution via density functional theory and self-consistent reaction field methods J. Phys. Chem. A 2002, 106, 1327-1335
47. Jaguar, version 7.5; Schrödinger, LLC: New York, 2008.
48. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
49. LigPrep, version 2.2; Schrödinger, LLC: New York, 2005.
50. Molecular Operating Environment, version 2008.10; Chemical Computing Group: Montreal, Quebec, Canada, 2008.